EVALUATION OF EFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C, CAUSED BY HCV GENOTYPE 6

EVALUATION OF EFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C, CAUSED BY HCV GENOTYPE 6

Objectives: Evaluating the effectiveness of 2 therapeutic schemes for chronic hepatitis C (genotype 6) which combined sofosbuvir and ribavirin, one of them also included pegylated interferon. Materials and methods: The study included 110 patients with chronic hepatitis C (genotype 6), who have under...

Full description

Bibliographic Details
Main Authors:	D. A. Lioznov, N. H. Chung, S. L. Nikolaenko, T. B. Trung, F. T. Lan, N. D. Phong
Format:	Article
Language:	Russian
Published:	Journal Infectology 2017-04-01
Series:	Журнал инфектологии
Subjects:	chronic hepatitis c genotype 6 treatment sofosbuvir vietnam
Online Access:	https://journal.niidi.ru/jofin/article/view/566

Similar Items

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
by: L.P. Zanaga, et al.

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
by: L.P. Zanaga, et al.
Published: (2016-10-01)

Safety and efficacy of combination therapy (Simeprevir/Sofosbuvir) in the treatment of chronic HCV genotype IV patients
by: Engy A. Wahsh, et al.
Published: (2018-03-01)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
by: Mir F, et al.
Published: (2017-02-01)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C
by: Jyh-Jou Chen, et al.
Published: (2022-11-01)

Effectiveness of sofosbuvir-based treatments for patients with hepatitis C virus genotype 6 infection: a real-world study from East China
by: Fan-Rong Jiang, et al.
Published: (2024-11-01)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
by: Tatsuo Kanda, et al.
Published: (2017-05-01)

Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
by: Eun Sun Jang, et al.
Published: (2020-11-01)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
by: Mohammed A Babatin, et al.
Published: (2019-01-01)

Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
by: Jong Eun Yeon
Published: (2018-09-01)

Effectiveness comparison of patients with hepatitis C virus genotypes 1 or 4 therapies
by: Abdullah Althemery, et al.
Published: (2025-01-01)

EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS
by: Sumetha Yaseen, et al.
Published: (2020-04-01)

Treatment of Chronic HCV Infection with Direct Acting Antivirals
by: Bekhbold Dashtseren, et al.
Published: (2021-09-01)

Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial
by: Shafiq Ur Rehman Cheema, et al.
Published: (2019-11-01)

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study
by: Barnaby Flower, et al.
Published: (2023-01-01)

Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China
by: Abulitifu Y, et al.
Published: (2022-11-01)

Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan
by: Hung-Chih Chiu, et al.
Published: (2021-03-01)

Real-life results of sofosbuvir based therapy for patients with hepatitis C
by: D. G. Zhivitsa, et al.
Published: (2019-09-01)

CLINICAL AND LABORATORY CHARACTERISTICS OF CHRONIC HEPATITIS C IN VIETNAM ON THE EXAMPLE OF HO CHI MINH CITY HEPATOLOGY CLINIC
by: D. A. Lioznov, et al.
Published: (2016-12-01)

Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients
by: Jiayi Wang, et al.
Published: (2024-12-01)

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
by: Soon Kyu Lee, et al.
Published: (2022-11-01)

Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
by: Raissa M Arruda, et al.
Published: (2020-10-01)

Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans
by: Kendall R. Beck, et al.
Published: (2018-05-01)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
by: Fabrizio Fabrizi, et al.
Published: (2022-11-01)

Changes in tryptophan and phenylalanine in chronic HCV patients treated with direct acting antiviral (sofosbuvir)
by: Eman G. Behiry, et al.
Published: (2018-11-01)

Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis
by: Hee Yeon Seo, et al.
Published: (2020-05-01)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
by: Melissa J. Barber, et al.
Published: (2020-09-01)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real-world setting
by: Dorota Zarębska-Michaluk, et al.
Published: (2019-07-01)

Efficacy of Sovodak in the Management of Patients Co-infected with HIV/HCV
by: Mohammad Hossein Somi, et al.
Published: (2020-08-01)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
by: Noha Anwar Hassuna, et al.
Published: (2022-12-01)

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
by: Ahmed OA, et al.
Published: (2018-03-01)

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
by: Nadia Marascio, et al.
Published: (2019-05-01)

SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3
by: Arif Qayyum Khan, et al.
Published: (2021-02-01)

Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study
by: Ya-Chao Tao, et al.
Published: (2018-10-01)

Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
by: Inas E L-Khedr Mohamed, et al.
Published: (2021-04-01)

Hepatocellular Regeneration and Necrosis Markers in Chronic HCV Patients under Sofosbuvir-Based Regimen
by: Amr Alnoby*, et al.
Published: (2021-08-01)

Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis
by: Nghiem Xuan Hoan, et al.
Published: (2021-02-01)

Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done
by: Susana Llerena, et al.
Published: (2019-01-01)

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
by: Hyun Woong Lee, et al.
Published: (2017-09-01)

Meta-Analysis of the Effectiveness of Sofosbuvir-Based Regimens in Treating Hepatitis C Genotype 3
by: Hafsa Siddique, et al.
Published: (2024-07-01)